Taglich Brothers Initiates Coverage on Boston Therapeutics, Inc.

NEW YORK, NY--(Marketwire - Sep 7, 2012) - Taglich Brothers, Inc. announces it initiated coverage of Boston Therapeutics, Inc.

Boston Therapeutics, Inc. (OTCBB: BTHE), headquartered in Manchester, New Hampshire, is a development stage specialty pharmaceutical company that brings proprietary complex carbohydrate chemistry to bear on the commercialization of prescription therapies and over-the-counter dietary supplements that treat Type 2 diabetes. 

BTHE's two-pronged strategy aims to initially secure a medium-term revenue stream by distribution of SUGARDOWN, then commercialize it to leading prescription drug pipeline products. SUGARDOWN, an over-the-counter chewable dietary supplement developed to block the release of glucose into the bloodstream after meals, is currently BTHE's only commercialized product. It is sold in the US on the over-the-counter market via the Internet. SUGARDOWN is also sold by distribution partners in China and Italy. 

PAZ320, a chewable prescription drug currently in a phase II trial, is an adjunctive treatment that also blocks the release of glucose into the bloodstream after meals. IPOXYN is an injectable prescription drug in preclinical development that was developed as a universal carrier of oxygen; it is being evaluated for the relief of lower-limb ischemia in diabetics. A veterinary version, Oxyfex™, is also in development. Initiation of human studies on IPOXYN is targeted for 2013. Clinical studies of all of BTHE's products are ongoing.

The complete 19-page report is available at http://www.taglichbrothers.com.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. In July 2012 the company paid an initial monetary engagement fee of US$9,000 to Taglich Brothers, Inc. representing payment for the first six months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for a minimum of six more months for such services.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.